Oruka Therapeutics, Inc. (ORKA)

NASDAQ: ORKA · Real-Time Price · USD

73.99

-2.40 (-3.14%)

At close: Apr 28, 2026, 4:00 PM EDT

73.99

0.00 (0.00%)

After-hours: Apr 28, 2026, 4:01 PM EDT

-3.14% (1D)

Market Cap	3.71B
Revenue (ttm)	n/a
Net Income (ttm)	-84.31M
Shares Out	50.20M
EPS (ttm)	-1.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,758,058
Open	78.21
Previous Close	76.39
Day's Range	72.16 - 84.97
52-Week Range	8.91 - 91.00
Beta	n/a
Analysts	Strong Buy
Price Target	88.33 (+19.38%)
Earnings Date	May 13, 2026

About ORKA

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 68

Stock Exchange NASDAQ

Ticker Symbol ORKA

Website https://orukatx.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ORKA stock is "Strong Buy." The 12-month stock price target is $88.33, which is an increase of 19.38% from the latest price.

Price Target

$88.33

(19.38% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics ...

1 day ago - GlobeNewsWire

Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

Oruka Therapeutics Inc. (NASDAQ:ORKA) shares are up during Monday's premarket session following positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque ps...

1 day ago - Benzinga

Oruka Therapeutics Transcript: Status update

Interim phase II data for ORKA-001 in moderate-to-severe psoriasis show 63.5% PASI 100 at week 16, surpassing other IL-23 inhibitors and matching top IL-17A/F agents. Safety is favorable, and PK supports annual dosing. A 28-week update and pivotal trial planning are upcoming.

1 day ago - Transcripts

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, wit...

1 day ago - GlobeNewsWire

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standa...

2 days ago - GlobeNewsWire

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026

6 weeks ago - GlobeNewsWire

Oruka Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Ultra-long acting antibodies targeting IL-23p19 and IL-17AF aim to transform psoriatic disease care with annual or semi-annual dosing, high efficacy, and potential off-treatment remission. Key Phase II data for ORKA-001 is expected in the second half of the year.

6 weeks ago - Transcripts

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standar...

2 months ago - GlobeNewsWire

Oruka Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

The company is advancing two long-acting monoclonal antibodies for psoriatic disease, aiming for annual or biannual dosing and potential off-treatment remission. Key phase II data are expected in 2024–2025, with a strong financial position and innovative trial designs supporting differentiation from current standards.

3 months ago - Transcripts

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for OR...

3 months ago - GlobeNewsWire

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standar...

4 months ago - GlobeNewsWire

Oruka Therapeutics Announces New Board Member and Board Transition

Appoints accomplished commercial leader Chris Martin to its Board of Directors Appoints accomplished commercial leader Chris Martin to its Board of Directors

4 months ago - GlobeNewsWire

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission

5 months ago - GlobeNewsWire

Oruka Therapeutics Transcript: Stifel 2025 Healthcare Conference

Two lead monoclonal antibody programs are advancing in psoriatic disease, targeting once or twice-yearly dosing and aiming for high efficacy and durable remission. Key phase II and I data readouts are expected through 2027, supported by a strong cash position.

5 months ago - Transcripts

Oruka Therapeutics to Present at Multiple November Investor Conferences

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standar...

6 months ago - GlobeNewsWire

Oruka Therapeutics Announces $180 Million Private Placement

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new stan...

7 months ago - GlobeNewsWire

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-t...

7 months ago - GlobeNewsWire

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 ...

9 months ago - GlobeNewsWire

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026

10 months ago - GlobeNewsWire

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standar...